Indolone-acetamide derivatives, processes for preparing them and their uses

1. A compound of formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,

wherein

R 1 is hydrogen,

R 2 is hydrogen or C 1-20 -alkyl,

NR 3 R 3a is a group of formula

R 4 is hydrogen,

R 5 is hydrogen; nitro; halogen; azido; cyano; —S—C 1-4 -alkyl; —SO—C 1-4 -alkyl; —SO 2 —C 1-4 -alkyl; —SONH 2 ; C 1-20 -alkyl unsubstituted or substituted by halogen; or C 1-20 -alkoxy unsubstituted or substituted by halogen,

R 6 is hydrogen, C 1-20 -alkyl or halogen,

R 7 is hydrogen, C 1-20 -alkyl or halogen,

Y is O, S, —CR 12 R 13 —, NR 14 or —C(═O)—

R 10 and R 10a are independently selected from hydrogen, C 1-4 -alkyl, halogen, hydroxy or methoxycarbonyl,

or R 10 and R 10a together form a C 3-6 -alkylene,

R 12 is hydrogen, C 1-4 -alkyl, halogen or hydroxy,

R 13 is hydrogen,

or CR 12 R 13 is dioxolanyl,

R 14 is aryl, heterocycle or a group of formula —V—R′ 5 ,

V is C 1-12 -alkylene,

R 15 is aryl or heterocycle,

n is 1.

2. A compound of formula I or a pharmaceutically acceptable salt thereof or stereoisomeric forms thereof,

wherein

R 1 is hydrogen,

R 2 is hydrogen or C 1-4 -alkyl,

NR 3 R 3a is piperidinyl unsubstituted or substituted by hydroxy; thiomorpholinyl; 4-oxooctahydro-1(2H)-quinolinyl; or a group of formula

R 4 is hydrogen,

R 5 is hydrogen; nitro; halogen; C 1-4 -alkyl, unsubstituted or substituted by halogen; or C 1-4 -alkoxy unsubstituted or substituted by halogen,

R 6 is hydrogen, C 1-6 -alkyl or halogen,

R 7 is hydrogen, methyl or halogen,

R 14 is pyridinyl; phenyl unsubstituted or substituted by halogen, hydroxy, C 1-4 -alkyl; or a group of formula —V—R 15 ,

V is unsubstituted C 1-4 -alkylene,

R 15 is phenyl or morpholinyl.

3. A compound according to claim 1 wherein R 2 is hydrogen or methyl.

4. A compound according to claim 1 wherein R 5 is halogen or trifluoromethyl.

5. A compound according to claim 1 wherein R 6 is hydrogen.

6. A compound according to claim 1 wherein R 7 is hydrogen, Br, or F.

7. A compound according to claim 1 wherein R 2 is C 1-20 -alkyl and the carbon atom to which R 2 is attached is in the “S”-configuration.

8. A compound selected from

5-chloro-1-[2-oxo-2-(4-pyridin-2-ylpiperazin-1-yl)ethyl]-1,3-dihydro-2H-indol-2-one;

5-chloro-1-{2-[4-(3-methylphenyl)piperazin-1-yl]-2-oxoethyl}-1,3-dihydro-2H-indol-2-one;

5(chloro-1-[2-(3-hydroxypiperidin-1-yl)-2-oxoethyl]-1,3-dihydro-2H-indol-2-one;

5-chloro-1-(2-oxo-2-thiomorpholin-4-ylethyl)-1,3-dihydro-2H-indol-2-one;

5-chloro-1-{2-oxo-2-[4-(2-phenylethyl)piperazin-1-yl]ethyl}-1,3-dihydro-2H-indol-2-one;

5-chloro-1-{2-[4-(4-hydroxyphenyl)piperazin-1-yl]-2-oxoethyl}-1,3-dihydro-2H-indol-2-one;

and

5-chloro-1-{2-[4-(2-morpholin-4-ylethyl)piperazin-1-yl]-2-oxoethyl}-1,3-dihydro-2H-indol-2-one.

9. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 in combination with a pharmaceutically acceptable diluent or carrier.